The pharmaceutical, biotech and medical device marketplaces are rapidly changing due to new medicines, new technologies, new therapeutic approaches and a challenging regulatory environment. In order to ensure the success of a new product, companies find it essential to educate the marketplace.
The Diabetes segment, along with cardiovascular disease (due to the FDA’s recent inclusion of cardiovascular risk factors when assessing anti-diabetes drugs seeking FDA approval), has seen much attention during recent years, including the emergence of many therapies aimed at treating Diabetes and its co-morbid diseases. For example, some companies are developing Diabetes vaccines.
Best Practices, LLC designed this report study to explore the best practices in educating, informing and preparing the marketplace for new diabetes products – through Physician, Patient, and Payer education and publications, advocacy and communication strategies. Specific topics covered in this report include:
- Identifying key education tactics for thought leaders, physicians, patients, and payers
- Assessing key market-education practices, including thought-leader services; Medical Education; scientific publications; patient advocacy and education; clinical trials and payer education
- Identifying key timing factors and education mix
- Describing critical market entry pitfalls and future trends
The results provided in this report include key benchmark metrics, executive insights, and recommendations that Medical Education and Marketing executives can optimize their utilization of current best practices and emerging trends to ensure a successful new product launch.